OBJECTIVE: In the US the incidence of neonatal abstinence syndrome (NAS) is rising, and both maternal opioid and psychotropic use have been implicated as independent risk factors. Our objective was to determine the association between maternal co-prescription to opioid and psychotropic medications and NAS compared to either opioids or psychotropics alone. STUDY DESIGN: A retrospective observational study of the [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] MarketScan database, a nationwide de-identified population of commercial insurance beneficiaries. Our primary outcome was NAS identified by diagnosis codes (ICD-9 779.5x). Our exposure was outpatient opioid and psychotropic co-prescription compared to psychotropics only and opioids only. Among co-prescribed women, we conducted subgroup analyses among women prescribed >1 type of psychotropic, opioid prescription >30 days (i.e. chronic use), coprescription during the same trimester, and prescription of gabapentin and benzodiazepine. Multivariable logistic regression models were used, adjusting for age, insurance type, dependent children, diagnosis codes for alcohol, tobacco, or illicit drug use, and US region to determine the association between maternal co-prescription and NAS.
RESULTS:
We identified 958,274 pregnant women with live births >21 weeks; 94,588 (9.9%) had only an opioid prescription, 55,285 (5.8%) had only a psychotropic prescription, and 19,884 (2.1%) had both. The frequency of NAS was significantly higher with co-prescription compared to either opioids or psychotropics (1.3% vs. 0.2%, 0.2%; p<0.0001); and increased further among subgroups of co-prescribed women. The adjusted odds of NAS for infants with mothers with co-prescription was 3.95 (95% CI: 3.22-4.85) compared to opioids only, and 6.10 (95% CI: 4.73-7.88) compared to psychotropics only (Table 1) . Among co-prescribed women, opioid prescription >30 days (vs. 30 days), and co-prescription during the same trimester (vs. no trimester with co-prescription) further increased the adjusted odds of NAS (Table 2) . CONCLUSION: Among commercially insured US pregnant women, compared to either prescription type alone, co-prescription of opioids and psychotropic medications is associated with significantly greater risk of NAS. These findings suggest that the evidence-based use of opioids and psychotropics for maternal pain and mental health disorders could decrease the rising rate of NAS.
567 Co-prescription of opioids and psychotropics among commercially insured US pregnant women and adverse pregnancy outcome University of North Carolina, Chapel Hill, NC, 2 University of Utah, Salt Lake City, UT OBJECTIVE: Both opioid or psychotropic prescription during pregnancy are independently associated with adverse pregnancy outcomes; however, the impact of co-prescription of opioids and psychotropics is not known. Our objective was to estimate the association between co-prescription of opioid and psychotropic medications in pregnancy and perinatal outcomes, including preterm birth (PTB) <37 weeks' gestation, cesarean delivery, and duration of hospitalization for delivery, compared to opioids only, psychotropics only, and no prescription. STUDY DESIGN: A retrospective observational study of the [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] MarketScan database, a nationwide de-identified population of commercial insurance beneficiaries. Our primary exposure was outpatient co-prescription of both opioids and psychotropics during pregnancy compared to 1) psychotropic only, 2) opioids only, and 3) neither. Our primary outcome was PTB <37 weeks, and, secondarily, PTB<34 weeks, cesarean delivery and duration of delivery hospitalization. We used multivariable logistic regression modeling, adjusting for maternal age, insurance type, dependent children, diagnosis codes of alcohol, tobacco, or illicit drug use, and US region to determine the association between co-prescription and pregnancy outcomes. RESULTS: Among 958,274 assessed pregnant women, 94,588 (9.9%) had only an opioid prescription, 55,285 (5.8%) had only a psychotropic prescription, and 19,884 (2.1%) had both. Women with opioids and psychotropics co-prescription during pregnancy were more likely to have a PTB compared to those who were prescribed opioids only (11.5% vs. 8.7%; AOR: 1.33; 95% CI: 1.26-1.40), psychotropics only (9.1%; AOR: 1.32; 95% CI: 1.25-1.39), and no prescription (7.0%; AOR: 1.70; 95% CI: 1.62-1.78). Women with coprescriptions were generally more likely to have a PTB<34 weeks, deliver via cesarean delivery, and have a longer hospitalization duration for both vaginal and cesarean deliveries compared to women with prescriptions for opioids only, psychotropics only, and no prescription (Table 1) . CONCLUSION: Among commercially insured US pregnant women, coprescription of opioids and psychotropics increases risk for PTB, as well as cesarean delivery and duration of delivery hospitalization, compared to prescription to either alone or no prescription. Further studies are needed to understand the relationship between opioids and psychotropics in pregnancy and adverse pregnancy outcomes.
568 Association of chorioamnionitis and its duration with neonatal morbidity and mortality OBJECTIVE: Chorioamnionitis, or intraamniotic infection, may complicate >50% of preterm births and is frequently diagnosed among term women in labor. There is a lack of recent, populationlevel data from both preterm and term infants to quantify the impact of chorioamnionitis on neonatal outcomes. We investigated the association of chorioamnionitis, and secondarily its duration, on neonatal morbidity and mortality for infants born <34 weeks versus 34 weeks gestation. STUDY DESIGN: A multi-site, nationally representative, observational study of singleton deliveries from the U.S. Consortium on Safe Labor Study. The primary exposure was chorioamnionitis, and secondarily, the duration of chorioamnionitis measured by the duration of intrapartum antibiotic therapy. The primary composite neonatal outcome included: pneumonia, seizure, necrotizing enterocolitis, sepsis, periventricular, intraventricular or cerebral hemorrhage, mechanical ventilation, and neonatal death. Logistic regression with generalized estimating equations was used, adjusting for maternal age, parity, race, pre-gestational diabetes, chronic hypertension, mode of delivery, year of delivery, and infant gender. RESULTS: Among 221,274 deliveries, 9,633 (4.4%) were <34 weeks. Chorioamnionitis was 4-times more frequent <34 weeks compared to 34 weeks (8.6% vs. 1.9%; p<0.001). The adjusted odds of the composite neonatal adverse outcome <34 weeks was approximately 2-fold higher among infants exposed to chorioamnionitis versus those who were not (62.0% vs. 47.7%; adjusted odds ratio, AOR: 1.93; 95% CI: 1.32 e 2.84), and was approximately 3.5-fold higher for infants born 34 weeks (9.2% vs. 2.5%; AOR: 3.44; 95% CI: 2.45 e 4.81) (Table) . The odds ratios for adverse neonatal outcomes were stable across the estimated duration of chorioamnionitis for infants born both <34 weeks and 34 weeks. CONCLUSION: In a large nationally representative sample of US births, chorioamnionitis was associated with an approximately 2-and 3.5-fold increased odds of neonatal morbidity and mortality <34 and 34 weeks, respectively, regardless of its estimated duration. These data provide a further evidence base to guide obstetric and pediatric providers in the timely management of a common infectious condition to improve neonatal health. OBJECTIVE: Despite efforts to decrease the rate of stillbirth including the use of antepartum fetal surveillance, stillbirth rates remain high in the United States. We aimed to estimate the incidence of stillbirth and to identify modifiable maternal risk factors associated with stillbirth. STUDY DESIGN: This retrospective cohort study included all singleton pregnancies with a normal anatomic survey at a single, academic tertiary care center between 17 and 23 weeks gestation from March 2010 to June 2017. Our primary outcome was the incidence of stillbirth, defined as fetal death in utero after 20 weeks gestation. Univariate analyses were used to identify potential maternal risk factors for stillbirth. Logistic regression was used to adjust for confounders. RESULTS: Of 24,711 pregnancies meeting inclusion criteria, stillbirth occurred in 262 pregnancies (1.1%, 95% CI 0.9-1.2%). In
